Research programme: Alzheimer's disease therapies - Neurologix
Latest Information Update: 24 Aug 2009
At a glance
- Originator Neurologix
- Class Gene therapies
- Mechanism of Action Amyloid inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 18 May 2005 Preclinical trials in Alzheimer's disease in USA (unspecified route)